Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients

Dry Eye Syndromes Clinical Trial

Official title:

Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02533154
• Other study ID #: OPHT-280515
• Status: Recruiting
• Phase: Phase 4
• Start date: July 27, 2015
• Est. completion date: October 2023

Study information

• Verified date: April 2022
• Source: Medical University of Vienna
• Contact: Gerhard Garhöfer, MD
• Phone: +43 1 40400
• Email: gerhard.garhoefer[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Benzalkonium chloride (BAC) is a preservative, which is a component of more than 70% of topical ophthalmic drugs. Although BAC is a preservative with an excellent antibacterial spectrum, it has also been shown to induce toxic effects to the ocular surface. Several studies have indicated that BAC may also have altering effects on the bacterial flora of the conjunctiva.

Since dry eye syndrome (DES) is a very common and multifactorial disease of the ocular surface and the tear fluid resulting in tear film instability, inflammation of the ocular surface, symptoms of discomfort and visual impairment, there are many different preserved as well as preservative-free ophthalmic preparations of ocular lubricants for the treatment of DES. Unpublished data from our department shows differences between artificial tears for the treatment of DES with and without BAC in bacterial culture.

Therefore, the aim of this study is to investigate the effect of artificial tear eyedrops with and without BAC on the conjunctival bacterial flora. For this 40 patients with mild or moderate dry eye syndrome with no use of artificial tears in the 4 weeks preceding the study will be recruited and treated either with the preservative-free "Prosicca sine" eyedrops or the BAC containing "Prosicca" eyedrops for one month. Conjunctival samples will be collected of one eye of each patient before and after the 1-month treatment period to compare the conjunctival bacterial flora of the two treatment groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Men and women aged between 18 and 75 years.

• Signed and dated written informed consent.

• History of dry eye syndrome for at least 3 months

• Tear Break Up Time (BUT) = 10 seconds or Schirmer I test = 10 mm and = 2mm

• Normal ophthalmic findings except dry eye syndrome, ametropia < 6 Dpt.

• Recommended use of topical lubricants, but no administration of topical lubricants 4 weeks preceding the first study day.

Exclusion Criteria:

• History or presence of ocular disease judged by the investigator as incompatible with the study.

• Any other topical ocular treatment than the study medication in the 4 weeks preceding the first study day and during the treatment period.

• Wearing of contact lenses.

• Symptoms of a clinically relevant illness in the 3 weeks before the first study day.

• Participation in a clinical trial in the 3 weeks preceding the first study day.

• Pregnancy, lactation.

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Keratoconjunctivitis Sicca

Intervention

Drug:
• Prosicca
Prosicca eyedrops Dosage: on demand Route of administration: topical
• Prosicca sine
Prosicca sine eyedrops Dosage: on demand Route of administration: topical

Other:
• Bacterial culture
bacterial cultures obtained with conjunctival swabs

Locations

Country	Name	City	State
Austria	Department of Clinical Pharmacology, Medical University of Vienna	Vienna
Austria	Department of Clinical Pharmacology, Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of colony forming units (CFU) in bacterial culture of conjunctival swab		1 month
Secondary	Tear Break Up Time (BUT)		1 month
Secondary	Schirmer I test		1 month
Secondary	OSDI© score		1 month
Secondary	Instillation frequency		1 month